Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”; 3692.HK), a leading biopharmaceutical company in China, today announced a strategic collaboration and licensing agreement for almonertinib with EQRx™, a biopharmaceutical company committed to making innovative medicines at dramatically lower prices for the benefit of people and society.
With 1,400 professionals across R&D, Hansoh ranks top 2 in innovation among all biotech and pharmaceutical companies in China based on new molecular entity INDs submitted for clinical development since 2011.Hansoh Pharma’s 2018 revenue was US$1.1 billion, representing a year-over-year growth of 25%. Hansoh Pharma (3692:HK), a leading biopharmaceutical company in China, is committed to discovering and developing life-changing medicines to help patients conquer serious diseases and disorders. Hansoh will receive undisclosed upfront, regulatory and commercial milestone payments, as well as royalty payments. Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma; 3692.HK), a leading biopharmaceutical company in China, today announced a strategic collaboration and licensing agreement for almonertinib with EQRx„¢, a biopharmaceutical company committed to making innovative medicines at dramatically lower prices for the benefit of people and society. Powered by Madgex Job Board Software Almonertinib provides a highly efficacious treatment option with favorable safety profile for advanced NSCLC patients. About 40% of these are EGFR mutation-positive and approximately 50% of patients treated with first- or second-generation EGFR TKI therapy will acquire resistance related to the T790M mutation. This agreement adds a high quality, clinically significant therapy for treating lung cancer, while bringing EQRx a step closer to making critically important medicines affordable for people who need them. Almonertinib 110mg once-daily tablet is a medicine indicated for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an NMPA-approved test, who have progressed on or after prior EGFR TKI therapy. Create a professional pharma logo in minutes with our free pharma logo maker. “We look forward to working closely with EQRx for the benefit of lung cancer patients around the world.” Hansoh Pharma (3692.HK), a leading biopharmaceutical company in Asia, is committed to discovering and developing life-changing medicines to help patients conquer serious diseases and disorders. For more information, please visit Viela Bio, headquartered in Gaithersburg, Maryland, is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases by selectively targeting shared critical pathways that are the root cause of disease.© 1985 - 2020 BioSpace.com. EQRx„¢ is committed to making innovative medicines at dramatically lower prices for the benefit of people and society.
[1] In March 2020, almonertinib received marketing authorization from the NMPA in China for second-line treatment in patients with EGFR T790M mutation-positive NSCLC. As the world’s largest company for contract development and manufacturing, our Pharma Biotech & Nutrition segment is recognized for its reliable, high-quality services, regulatory track record, global footprint, innovative technology platforms and extensive experience. We look forward to working closely with EQRx for the benefit of lung cancer patients around the world. “Knowing that my small contribution will have an impact on a global scale is what has always driven me to develop novel therapeutics.”“Making new therapies available to patients in need is what it is all about.”“Viela has the established technical, quality system and ethics of a Big Pharma, with the benefits of a small biotech…”“We have a lot of really smart people, and a great deal of collaboration internally and externally.”At Viela, we are working to redefine the treatment of autoimmune disease by focusing on pathways shared across various diseases.
These may be complex services or products and we request the readers to consider this purely from an educational standpoint. Viela expects to file for a Biologics License Application with the U.S. Food and Drug Administration (FDA) in mid-2019.Inebilizumab is a humanized monoclonal antibody that binds with high affinity to CD19, a protein expressed on a broad range of B cells, including antibody-secreting plasmablasts and plasma cells. EQRx and Hansoh will seek to jointly conduct global studies to further expand the potential of almonertinib as a monotherapy and in combination therapy settings.
We are excited to add almonertinib to our ever expanding pipeline of innovative medicines, said Alexis Borisy, chairman, founder and chief executive officer of EQRx. The information available on this website is purely for educational and informational purposes only. After binding to CD19, these cells are rapidly depleted from circulation. You consent to our cookies if you continue to use our website. These cookies will be stored in your browser only with your consent. Hansoh Pharma (3692.HK), a leading biopharmaceutical company in Asia, is committed to discovering and developing life-changing medicines to help patients conquer serious diseases and disorders. Together, we will endeavor to advance inebilizumab as quickly as possible for patients in China, as well as seek to broaden the potential of inebilizumab via combination therapies.”Viela recently presented positive results from a pivotal study of inebilizumab in patients with neuromyelitis optica spectrum disorder (NMOSD) – a rare autoimmune disease characterized by unpredictable attacks that often lead to severe, irreparable disability including blindness and paralysis.